Published in Immunotherapy Weekly, October 13th, 2004
"Herpes simplex virus (HSV) infections affect nearly 150 million Americans, of which 40-60 million are infected with HSV-2 and up to an additional 1 million new individuals are infected each year. The current treatment for HSV infections are nucleoside analogues such as acyclovir, valacyclovir and famciclovir," wrote investigators an Expert Opinion on Therapeutic Patents review.
"Despite the safety and efficacy of these agents," said S.M. Firestine and colleagues, "many of these agents possess limited oral bioavailability,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.